In the Journals

Patients with RA had increased odds for recurrence of acute coronary syndrome

Compared with the general population, patients with rheumatoid arthritis are at an increased risk for recurrence of acute coronary syndrome, according to a recently published study.

“[Our] study suggests that by and large, the use of secondary preventive drugs in [rheumatoid arthritis] RA is not markedly lower than in [acute coronary syndrome] ACS in general, yet patients with RA are at increased risk of recurrent ACS as well as mortality following ACS,” the researchers wrote. “Consequently, from an aetiological point of view, additional factors are likely to drive the impaired outlook and will be important to identify.”

Investigators assessed 1,135 patients with RA and 3,184 patients without RA. All patients developed ACS between 2007 and 2010. There was an increased risk for ACS recurrence at 1 year (hazard ratio = 1.3) and after adjustment for baseline comorbidities (hazard ratio = 1.38) for the RA group. In addition, there was reduced statin use among specific subgroups of ACS.

“Clinically, among patients with coronary artery disease, those with RA should be recognized as patients at elevated risk among whom preventive measures may be of particular importance,” the researchers wrote. – by Will Offit

 

Disclosures: One researcher reports he received personal fees from AstraZeneca, MSD and Aspen outside of the submitted work. Please see the full study for a list of all other authors’ relevant financial disclosures.

Compared with the general population, patients with rheumatoid arthritis are at an increased risk for recurrence of acute coronary syndrome, according to a recently published study.

“[Our] study suggests that by and large, the use of secondary preventive drugs in [rheumatoid arthritis] RA is not markedly lower than in [acute coronary syndrome] ACS in general, yet patients with RA are at increased risk of recurrent ACS as well as mortality following ACS,” the researchers wrote. “Consequently, from an aetiological point of view, additional factors are likely to drive the impaired outlook and will be important to identify.”

Investigators assessed 1,135 patients with RA and 3,184 patients without RA. All patients developed ACS between 2007 and 2010. There was an increased risk for ACS recurrence at 1 year (hazard ratio = 1.3) and after adjustment for baseline comorbidities (hazard ratio = 1.38) for the RA group. In addition, there was reduced statin use among specific subgroups of ACS.

“Clinically, among patients with coronary artery disease, those with RA should be recognized as patients at elevated risk among whom preventive measures may be of particular importance,” the researchers wrote. – by Will Offit

 

Disclosures: One researcher reports he received personal fees from AstraZeneca, MSD and Aspen outside of the submitted work. Please see the full study for a list of all other authors’ relevant financial disclosures.